Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bet v 1 birch pollen allergen extract
- Development stage
- Unknown
- Lead developer
- Universität Leipzig
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Bet v 1 birch pollen allergen extract is a biologic allergen immunotherapy (AIT) agent consisting of the natural major allergen from birch pollen (*Betula verrucosa*). It is administered via subcutaneous injection (SCIT) to desensitize patients with birch pollinosis. The primary rationale for its use in the BASALIT (Birch Associated Soy Allergy and Immuno-Therapy) trial is to treat pollen-food allergy syndrome, specifically the immediate-type soy allergy caused by cross-reactivity between the birch allergen Bet v 1 and the soy allergen Gly m 4. By modulating the IgE-mediated immune response and inducing immunological tolerance, the extract aims to reduce allergic symptoms triggered by both birch pollen and soy consumption.
- Other names
- Bet v 1birch pollen allergen extractnatural Bet v 1 protein
02
Targets
Bet v 1-sIgE (Bet v 1-specific IgE)Bet v 1IgE (Immunoglobulin E)
Beyond the preview
Go deeper on bet v 1 birch pollen allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bet v 1 birch pollen allergen extract.